SmartCell Technology

Verdagy secures Series B funding led by Temasek and Shell Ventures

Retrieved on: 
Tuesday, August 8, 2023
SunPower, SmartCell Technology, Solid oxide electrolyzer cell, Hydrogen, MOSS, Fortera Stadium, Watt, Steel, Movement, Wind, Membrane, Renewable energy, CAPEX, Temasek, Ammonia, Series, Knowledge, Tesla, Investment, BlueScope, Electric battery

MOSS LANDING, Calif., Aug. 8, 2023 /PRNewswire/ -- Verdagy, a pioneer in scaling electrolyzer technologies for industrial markets, today announced the closing of a $73-million Series B funding round. Temasek and Shell Ventures co-led the Series B round, with participation from new global investors Bidra Innovation Ventures, BlueScope, Galp, Samsung Venture Investment, Toppan Ventures, Tupras Ventures, Yara Growth Ventures and Zeon Ventures.

Key Points: 
  • Temasek and Shell Ventures co-led the Series B round, with participation from new global investors Bidra Innovation Ventures, BlueScope, Galp, Samsung Venture Investment, Toppan Ventures, Tupras Ventures, Yara Growth Ventures and Zeon Ventures.
  • "Verdagy is rising to the challenge to accelerate the green hydrogen economy and decarbonize hard-to-abate sectors such as steel and ammonia production," said Vikas Gupta, Partner at Shell Ventures.
  • "The management team has a successful track record in scaling climate technologies from megawatts to gigawatts and they are committed to achieving the same at Verdagy."
  • "Verdagy is at an inflection point - going from proven technology to commercialization stage," said Amar Singh, Head of Group, Bidra Innovation Ventures.

Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial

Retrieved on: 
Tuesday, November 1, 2022
Health, COVID-19, Clinical Trials, Research, Pharmaceutical, Science, CEO, Pfizer, II, CRO, Vaccination, Merck, Merck & Co., Research, Omicron, COVID-19, Johnson & Johnson, Immune system, GMP, Safety, Vaccine, Martek Biosciences Corporation, AstraZeneca, Contract research organization, SmartCell Technology, Therapy, Infection, Autoimmune disease, Laboratory, Pharmaceutical industry

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced top-line clinical results for its Phase II COVID-19 universal booster vaccine, AKS-452.

Key Points: 
  • Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced top-line clinical results for its Phase II COVID-19 universal booster vaccine, AKS-452.
  • The vaccine was well tolerated with data indicating a favorable safety profile, similar to that of the registered vaccines.
  • The favorable safety and immunogenicity profiles at the interim analysis of this study, particularly against variants, support a Phase III universal booster study for AKS-452, said Todd Zion, Ph.D., President & CEO of Akston Biosciences.
  • A 1,600 subject Phase II/III clinical trial of AKS-452 as a two-dose primary vaccine was completed earlier this year in India.

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

Retrieved on: 
Friday, June 24, 2022
COVID-19, Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Process, Research, Immortalised cell line, STAR, COVID-19, Delta, Company, Longevity, Volunteering, Serum, Seroconversion, ANVISA, Vaccine, EUA, Stelis, Efficiency, WHO, RNA transfection, Fahrenheit, BSE, Population, Immunization, UK, Omicron, GMP, PD, National Stock Exchange of India, Merck, USFDA, Martek Biosciences Corporation, Insulin glargine, Insulin, Global, Diabetes, CEO, DPH, Peptide, Insulin lispro, Immunoglobulin G, Insulin aspart, Partnership, Technology, Temperature, Merck & Co., Leadership, Stride, SmartCell Technology, National Stock Exchange, Porantha Veeda Puguntha Veeda, CDMO, COVID-19 vaccine, Maintenance, Developing country, Safety, Immunity, Pharmaceutical industry, Fine chemical, Phase

The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).

Key Points: 
  • The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).
  • Akston and Strides group have already signed a licensing, manufacturing, and commercialization agreement to launch this vaccine worldwide as AmbiVax-CTM.
  • The vaccine is a reliable, accessible alternative in these regions, allowing immunization and longevity of immunity with the boosters against the Covid variants of concern.
  • Biolexis Private Limited (Biolexis) is an emerging biotech and vaccine company capable of developing and commercializing products for the Global markets.

Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster

Retrieved on: 
Thursday, May 12, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, RNA transfection, Education, Janssen, Disease, II, Merck & Co., GMP, Multimedia, Vaccine, SmartCell Technology, Coronavirus, Health, Phase, University Medical Center Groningen, COVID-19, Merck, Volunteering, Research, Johnson & Johnson, Contract research organization, Time, CRO, Immunity, EMA, Hospital, Autoimmune disease, RBD, Therapy, Immune system, Ageing, Martek Biosciences Corporation, AstraZeneca, CEO, Pharmaceutical industry, Pfizer

View the full release here: https://www.businesswire.com/news/home/20220511006129/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220511006129/en/
    The first volunteer receives Akston Biosciences COVID-19 booster vaccine, AKS-452, as part of a Phase II trial in the Netherlands.
  • Schelto Kruijff, M.D., Ph.D., the principal investigator at the UMCG for the AKS-452 Phase I and Phase II primary vaccine trials, is serving in the same capacity for the booster trial.
  • The trial is managed by TRACER Europe B.V., a CRO specializing in fast-track clinical trials and which conducted the Phase I and II trials for AKS-452.
  • A 1,600 subject Phase II/III clinical trial of AKS-452 as a two-dose primary vaccine is currently underway in India.

Akston Biosciences CEO to Present at the World Vaccine Congress

Retrieved on: 
Tuesday, April 12, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CEO, DNA, Delta, WVC, Marriott Marquis, COVID-19, Research, GMP, Washington Marriott Marquis, Pfizer, Patient, Infection, Autoimmune disease, Merck, Martek Biosciences Corporation, Vaccine, Johnson & Johnson, RBD, Coronavirus, SmartCell Technology, Vie, EUA, COVID-19 vaccine, RNA transfection, Merck & Co., Risk, Omicron, Congress, Pharmaceutical industry

Akston Biosciences Corporation , a developer of new classes of biologics, announced that its president and CEO, Todd Zion, Ph.D., has been invited to present at this years World Vaccine Congress (WVC).

Key Points: 
  • Akston Biosciences Corporation , a developer of new classes of biologics, announced that its president and CEO, Todd Zion, Ph.D., has been invited to present at this years World Vaccine Congress (WVC).
  • In addition, the companys Fc-fusion protein platform has been shortlisted in the best new vaccine technology category of the World Vaccine Congress Vaccine Industry Excellence (ViE) Awards.
  • Its an honor to be invited to present a clinical update of Akstons COVID-19 vaccine at the World Vaccine Congress.
  • Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies.

Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine

Retrieved on: 
Thursday, April 7, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Merck & Co., Population, Therapy, WHO, Vaccination, Interim, Partnership, ANVISA, Clinical trial, Multimedia, Fahrenheit, Coronavirus, Martek Biosciences Corporation, UK, Phase, Vaccine, EUA, Research, Delta, Merck, CEO, Developing country, Autoimmune disease, Immunoglobulin G, McMaster University Medical Centre, Omicron, USFDA, Safety, SmartCell Technology, RNA transfection, Emergency Use Authorization, CDSCO, COVID-19, Porantha Veeda Puguntha Veeda, COVID-19 vaccine, RBD, GMP, Patient, Shrikant Deshpande, Volunteering, Infection, Pharmaceutical industry

Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced today that the first volunteers in a Phase II/III clinical study of AKS-452, its low cost, shelf stable protein subunit COVID-19 vaccine, were dosed in India.

Key Points: 
  • Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced today that the first volunteers in a Phase II/III clinical study of AKS-452, its low cost, shelf stable protein subunit COVID-19 vaccine, were dosed in India.
  • View the full release here: https://www.businesswire.com/news/home/20220406006130/en/
    The first volunteer receives Akston Biosciences COVID-19 vaccine, AKS-452, as part of a Phase II/III double-blind placebo-controlled study in India.
  • (Photo: Business Wire)
    The multicenter trial will complete the enrollment of 1,500 healthy volunteers, age 18 and older, who will receive two 90 g doses 28 days apart.
  • This clinical trial represents an important step in the development of protein-based COVID-19 vaccines, said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster

Retrieved on: 
Thursday, March 31, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Other Health, Risk, Merck & Co., Therapy, Janssen, Vaccination, DNA, Trial of the century, Volunteering, Martek Biosciences Corporation, Coronavirus, II, University Medical Center Groningen, Phase, Vaccine, EUA, Research, Serum, Hospital, Stride, Merck, CEO, Severe acute respiratory syndrome coronavirus 2, Immunity, Health, Developing country, AstraZeneca, Autoimmune disease, Immune system, SmartCell Technology, RNA transfection, Contract research organization, Time, COVID-19, CRO, Ageing, EMA, COVID-19 vaccine, RBD, GMP, Education, Seroconversion, Patient, Disease, Johnson & Johnson, Infection, Pharmaceutical industry, Pfizer, AKS-452, UNIVERSITY MEDICAL CENTER GRONINGEN, TRACER, AKSTON BIOSCIENCES

The trial is managed by TRACER Europe B.V., a CRO specializing in fast-track clinical trials and which oversaw the Phase I and II trials for AKS-452.

Key Points: 
  • The trial is managed by TRACER Europe B.V., a CRO specializing in fast-track clinical trials and which oversaw the Phase I and II trials for AKS-452.
  • Ph.D., the principal investigator at the UMCG for the AKS-452 Phase I and Phase II primary vaccine trials, will serve in the same capacity for the booster trial.
  • Given the apparent waning of immune response, a promising vaccine candidate like AKS-452 could be an effective booster.
  • A 1,600 subject Phase II/III clinical trial of AKS-452 as a two-dose primary vaccine is currently underway in India.

Akston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine

Retrieved on: 
Tuesday, February 8, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, SARS, Merck & Co., Martek Biosciences Corporation, Research, Autoimmune disease, GMP, Â, Patient, Seroconversion, SmartCell Technology, Severe acute respiratory syndrome coronavirus 2, CEO, COVID, Therapy, Coronavirus, DPH, B.1.1.7, Merck, Infection, RBD, COVID-19, Vaccine, Pharmaceutical industry, Vaccine, AKS-452, Akston Biosciences, AKS-452, AKSTON BIOSCIENCES

Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced publication of positive results from a 60-subject, open-label, Phase I trial of AKS-452, its shelf stable protein subunit COVID-19 vaccine candidate.

Key Points: 
  • Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced publication of positive results from a 60-subject, open-label, Phase I trial of AKS-452, its shelf stable protein subunit COVID-19 vaccine candidate.
  • The trial met all primary and secondary endpoints, indicating minimal reactogenicity and optimized immunogenicity.
  • A recombinant subunit vaccine, AKS-452 comprises an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain (RBD) antigen that is engineered to preserve effectiveness against viral variants.
  • Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies.

Akston Biosciences Announces Positive Top-Line Data From Phase II Study of COVID-19 Vaccine in the Netherlands

Retrieved on: 
Wednesday, December 22, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, RBD, DPH, Patient, Merck, Coronavirus, Fatigue, CEO, Infection, Merck & Co., Seroconversion, Plant, Phase, Serum, Therapy, Autoimmune disease, Refrigeration, List of life sciences, SmartCell Technology, Headache, COVID, Antibody, Injection site reaction, Safety, Research, GMP, Vaccine, RNA transfection, Pharmaceutical industry

Akston Biosciences , Inc. a developer of new classes of biologic therapeutics, today announced positive data from the Phase II clinical trial of its second-generation SARS-CoV2 vaccine candidate, AKS-452.

Key Points: 
  • Akston Biosciences , Inc. a developer of new classes of biologic therapeutics, today announced positive data from the Phase II clinical trial of its second-generation SARS-CoV2 vaccine candidate, AKS-452.
  • It showed the vaccine induced a robust Th1/Th2 mixed immune response against the Receptor Binding Domain (RBD) of the coronavirus spike protein.
  • In the trials second arm, a 26-participant cohort received a single 90 g, which also contained an adjuvant.
  • We look forward to sharing data from the Phase II/III trial that will start next month in India.

IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology

Retrieved on: 
Wednesday, December 15, 2021
Biotechnology, Pharmaceutical, Optical, Health, Glaucoma, Company, Private Securities Litigation Reform Act, Duane syndrome, Macular degeneration, Insufflation, Cornea, Dry eye syndrome, Micelle, Patient, Therapy, SmartCell Technology, SYK, CB2, Program, Partnership, Ophthalmology, Pharmaceutical industry, TALLC, Inc., IACTA Pharmaceuticals, Inc., TALLC, INC., IACTA PHARMACEUTICALS, INC.

The agreement grants IACTA the use of TALLCs proprietary SmartCelle micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development.

Key Points: 
  • The agreement grants IACTA the use of TALLCs proprietary SmartCelle micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development.
  • IACTA plans to utilize TALLCs SmartCelle technology to deliver one or more of its novel ophthalmic therapeutics, as well as co-develop new ophthalmology therapeutic candidates that leverage IACTAs formulation and clinical expertise with TALLCs novel delivery technology.
  • TALLCs proprietary SmartCelle pan-ocular drug delivery technology employs 30nm micelles that enable delivery of difficult to formulate drugs into corneal and retinal tissues after topical delivery.
  • IACTA is a registered trademark of Iacta Pharmaceuticals, Inc. SmartCelle is a trademark of Altus Formulation licensed to TALLC Inc. All other trademarks are owned by their respective owners.